Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
Updated data for Lilly's Inluriyo reinforce efficacy results as monotherapy and in combination with Verzenio® in ER+, HER2- advanced breast cancer
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
Lilly's Jaypirca significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
Lilly's Jaypirca met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica
U.S. FDA approves expanded indication for Lilly's Jaypirca , the first and only non-covalent BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
Lilly to present data from two positive Phase 3 studies of Jaypirca in chronic lymphocytic leukemia at the 2025 American Society of Hematology Annual Meeting
Goldgroup Enters Into Agreement To Sell Subsidiary Minera Apolo, S.A. de C.V., Disposing of Pinos Project
55 North Mining Appoints Wayne Parsons as Executive Chair; Strengthens Leadership as the Company Advances the Last Hope Gold Project
